Boehringer Ingelheim Pharmaceuticals Inc., et al. v. Zydus Pharmaceuticals (USA) Inc., et al.
| Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharmaceuticals Inc. and Boehringer Ingelheim International GmbH |
| Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited |
| 1:2019cv01501 |
| August 9, 2019 |
| US District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on September 11, 2019. A more recent docket listing may be available from PACER.
| Document Text |
|---|
Filing 12
SO ORDERED, re (83 in 1:18-cv-01689-CFC-SRF, 9 in 1:19-cv-01499-CFC, 8 in 1:19-cv-01498-CFC, 8 in 1:19-cv-01494-CFC, 7 in 1:19-cv-01492-CFC, 8 in 1:19-cv-01495-CFC, 8 in 1:19-cv-01501-CFC, 8 in 1:19-cv-01596-CFC, 9 in 1:19-cv-01500-CFC, 9 in 1:19-cv-01493-CFC, 8 in 1:19-cv-01594-CFC, 8 in 1:19-cv-01497-CFC, 7 in 1:19-cv-01496-CFC) STIPULATION Stipulation and [Proposed] Order for Consolidation. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 18-1689-CFC. Plaintiffs and Defendants shall follow the Scheduling Order entered in the Consolidated Action except for those deadlines outlined in this order. Signed by Judge Colm F. Connolly on 9/9/2019. Associated Cases: 1:18-cv-01689-CFC-SRF et al.(nmf)
|
| Case associated with lead case: Create association to 1:18-cv-01689-CFC-SRF. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 18-1689-CFC ONLY. (nmf) |
| Filing 11 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Cadila Healthcare Ltd. for Zydus Pharmaceuticals (USA) Inc. filed by Zydus Pharmaceuticals (USA) Inc.. (Phillips, John) |
| Filing 10 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Cadila Healthcare Limited. (Phillips, John) |
| Filing 9 ANSWER to #1 Complaint, Affirmative Defenses and, COUNTERCLAIM against Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Limited.(Phillips, John) |
| Filing 8 STIPULATION Stipulation and [Proposed] Order for Consolidation by Cipla Limited, Cipla USA, Inc., Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., MSN Laboratories Private Ltd., MSN Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Sun Pharmaceutical Industries, Inc., Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc.. (Phillips, John) |
| Filing 7 SUMMONS Returned Executed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corporation. Cadila Healthcare Limited served on 8/14/2019, answer due 9/4/2019. (Dellinger, Megan) |
| Filing 6 SUMMONS Returned Executed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corporation. Zydus Pharmaceuticals (USA) Inc. served on 8/14/2019, answer due 9/4/2019. (Dellinger, Megan) |
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:19-cv-01492-CFC et al.(nmg) |
| Summons Issued with Magistrate Consent Notice attached as to Cadila Healthcare Limited on 8/12/2019; Zydus Pharmaceuticals (USA) Inc. on 8/12/2019. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (kmd) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent C. H. Boehringer Sohn AG & Co. KG for Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc.. (kmd) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,258,637 B2. (kmd) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: May 10, 2019. Date of Expiration of Patent: April 3, 2034.Thirty Month Stay Deadline: 2/1/2022. (kmd) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (kmd) |
| Filing 1 COMPLAINT filed against Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2705832.) - filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corporation. (Attachments: #1 Exhibit 1, #2 Civil Cover Sheet)(kmd) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
